Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial-Reference-Cited by-同舟云学术

Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial

Published:2019-05 Issue:5 Volume:19 Page:487-496
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Kokai-Kun John F,Roberts Tracey,Coughlin Olivia,Le Chenxiong,Whalen Heidi,Stevenson Ralph,Wacher Vincent J,Sliman Joseph

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference29 articles.

1. Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach;Desai;BMC Infect Dis,2016

2. Burden of Clostridium difficile infection in the United States;Lessa;N Engl J Med,2015

3. Mortality and costs in Clostridium difficile infection among the elderly in the United States;Shorr;Infect Control Hosp Epidemiol,2016

4. Antibiotic therapy and Clostridium difficile infection—primum non nocere—first do no harm;Crowther;Infect Drug Resist,2015

5. Clostridium difficile infection;Smits;Nat Rev Dis Primers,2016

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ceftriaxone alters the gut microbiome composition and reduces alcohol intake in male and female Sprague–Dawley rats;Alcohol;2024-11

2. Fighting against Clostridioides difficile infection: Current medications;International Journal of Antimicrobial Agents;2024-07

3. Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options;Clinical Microbiology Reviews;2024-06-13

4. Breaking the Cycle of Recurrent Clostridioides difficile Infections: A Narrative Review Exploring Current and Novel Therapeutic Strategies;Journal of Pharmacy Practice;2024-05-13

5. New treatment approaches for Clostridioides difficile infections: alternatives to antibiotics and fecal microbiota transplantation;Gut Microbes;2024-04-09